Ketamine for Treatment-Resistant Depression: A Gateway to Novel Treatment Approaches.
Treatment-resistant depression (TRD) is a disabling and demoralizing phenomenon for patients and clinicians. For many years, treatment for depression has relied on the monoamine theory, with medications limited in efficacy and requiring prolonged use before any therapeutic effects are evident. The current article reviews novel approaches to pharmacological treatment of TRD, including N-methyl-D-aspartate glutamate receptor antagonists and other receptor agonists and antagonists beyond serotonin and norepinephrine. [Journal of Psychosocial Nursing and Mental Health Services, 56(10), 11-14.].